Thema: US45257U1088
IMNM, US45257U1088
don-3565699_1920.jpg - Foto: THN
Immunome stock: IM-1021 shows 53% lymphoma response rate
Immunome stock is set for an oncology data update at ASH after early IM-1021 results showed responses in heavily pretreated lymphoma patients. The Phase 1 study continues.
ad-hoc-news.de, vor 54 Minuten
IMNM, US45257U1088
Immunome clears FDA IND for IM-1340: what it means for Immunome ...
FDA cleared IM-1340's IND on September 30, 2026. For Immunome stock, a Phase 1 study is planned for the fourth quarter of 2026.
ad-hoc-news.de, 16.10.26 04:58 Uhr
IMNM, US45257U1088
Immunome stock advances clinical pipeline after FDA clearance ...
Immunome stock received FDA clearance for IM-1340 on September 30, 2026. Second-quarter adjusted EPS was USD -0.65 against USD -0.51 consensus.
ad-hoc-news.de, 07.10.26 00:28 Uhr
IMNM, US45257U1088
Immunome stock gets FDA clearance for fifth clinical program ...
